financetom
Business
financetom
/
Business
/
Builders FirstSource Q2: EPS Beat, Lower Sales And $1B Stock Buyback & More
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Builders FirstSource Q2: EPS Beat, Lower Sales And $1B Stock Buyback & More
Aug 6, 2024 10:33 AM

Builders FirstSource, Inc. ( BLDR ) shares are trading higher on Tuesday.

The company reported second-quarter adjusted earnings per share of $3.50, beating the street view of $3.02.

Quarterly sales of $4.456 billion missed the street view of $4.483 billion.

Net sales witnessed a 1.6% decrease, with core organic sales down 3.8% as Multi-Family continued to trend downward.

Gross profit margin fell 240 basis points to 32.8%, largely due to normalization effects in Multi-Family.

Adjusted EBITDA decreased by 12.9% to $669.7 million, driven by lower gross profit but partially offset by reduced operating expenses. The adjusted EBITDA margin declined 200 basis points to 15.0%, though it has stayed in the mid-teens or better for 13 consecutive quarters.

“As we continue to operate in this complex environment, I am proud of our resilient second quarter results highlighted by maintaining a mid-teens EBITDA margin, which demonstrates the strength of our differentiated business model and the hard work of our extraordinary team members,” commented Dave Rush, CEO of Builders FirstSource ( BLDR ). 

Also Read: Zelle Controversy Heats Up: JPMorgan Considers Legal Action

As of June-end, liquidity was approximately $1.7 billion, consisting of $1.6 billion in net borrowing availability under the revolving credit facility and $0.1 billion cash on hand.

Yesterday, the company’s Board of Directors authorized a new repurchase plan for up to $1.0 billion of its outstanding shares of common stock.

Year to date, the company has repurchased 5.9 million shares at an average price of $170.55 per share, totaling $1.0 billion. The company has reduced total shares outstanding by 4.4% in 2024.

In the second quarter, the company achieved about $37 million in productivity savings from operations and supply chain improvements. Year-to-date savings total approximately $77 million.

The company anticipates delivering between $90 million and $110 million in productivity savings for 2024.

Outlook: Builders FirstSource ( BLDR ) projects FY24 net sales between $16.4 billion and $17.2 billion, below the $17.631 billion estimate.

For FY24, the company expects a gross profit margin between 31.5% and 32.5%, adjusted EBITDA of $2.2 billion to $2.4 billion, and an adjusted EBITDA margin of 13.4% to 14.0%.

Price Action: BLDR shares are trading higher by 5.61% to $158.04 at last check Tuesday.

Read Next:

Boeing Poised for Free Cash Flow Surge Post-2024, Optimism Fueled by Production and New CEO: Goldman Sachs

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Troilus Loses 15% as Study Shows its Quebec Copper-Gold Project Can Support a US$1.07 Billion Mine Project
Update: Troilus Loses 15% as Study Shows its Quebec Copper-Gold Project Can Support a US$1.07 Billion Mine Project
May 14, 2024
11:39 AM EDT, 05/14/2024 (MT Newswires) -- Troilus Gold ( CHXMF ) shares fell 15% after the company on Tuesday reported the results of a feasibility study for its namesake copper-gold project in Quebec. Initial capital expenditure for the a mining project at the property is pegged at US$1.07 billion. The study outlined an after-tax net present value of US$884.5...
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
May 14, 2024
11:44 AM EDT, 05/14/2024 (MT Newswires) -- Kura Oncology ( KURA ) said Tuesday it completed the enrollment of 85 patients in the phase 2 segment of the clinical trial for potential leukemia drug Ziftomenib. The study evaluates Ziftomenib's effectiveness, safety and tolerance in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia, focusing on achieving a complete response, the...
Tesco's 10 million pound man - CEO's annual pay package doubles
Tesco's 10 million pound man - CEO's annual pay package doubles
May 14, 2024
LONDON (Reuters) - The boss of Tesco ( TSCDF ), Britain's largest supermarket group, saw his pay package more than double to almost 10 million pounds ($12.6 million) in its 2023/24 financial year, a period when millions of its customers battled a cost of living crisis. Tesco's ( TSCDF ) annual report, published on Tuesday, showed chief executive Ken Murphy...
Boeing Deliveries, Booked Gross Orders Decline in April
Boeing Deliveries, Booked Gross Orders Decline in April
May 14, 2024
11:40 AM EDT, 05/14/2024 (MT Newswires) -- Boeing ( BA ) reported Tuesday it delivered 24 aircraft in April, down from 26 a year earlier, according to data on its website. This figure is also down from 29 aircraft it delivered in March. The planemaker also booked seven gross orders in April, down from 34 a year earlier and from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved